New pill to treat multiple sclerosis

Apr 30, 2009

A new drug for multiple sclerosis can dramatically reduce the chances of a relapse or a deterioration of the condition, according to a new study from researchers at Queen Mary, University of London.

The results of a major trial presented at the Annual Meeting of the American Academy of Neurology in Seattle show that taking a course of cladribine tablets just a few times a year can reduce the chances of a relapse by well over 50 per cent. And patients who took part in the study suffered very few side effects.

If it becomes available to patients, cladribine will be the first licensed treatment for which does not involve regular injections.

is a disabling neurological condition which usually starts in young adulthood. It is the result of the body's own immune system damaging the central nervous system. This interferes with transmission of messages between the brain and other parts of the body and leads to problems with vision, muscle control, balance and memory.

For the 85,000 people in the UK who suffer from MS, the treatments which are currently available have to be given by frequent injections or intravenous infusions, and the benefits have to be weighed up against a number of side effects.

The new study involved over 1,300 MS patients who were followed up for nearly two years. Patients were given either two or four treatment courses of cladribine tablets per year, or a placebo. Each course consists of a single tablet per day for four or five days, adding up to just eight to 20 days of treatment each year. During the trial patients were monitored using MRI scans.

Compared to patients who were taking a placebo, those taking cladribine tablets were over 55 per cent less likely to suffer a relapse and 30 per cent less likely to suffer worsening in their disability due to MS.

The study's lead researcher is Professor Gavin Giovannoni of Barts and The London School of Medicine and Dentistry, part of Queen Mary, University of London. He said: "These results are really exciting. MS can be a very debilitating illness and at the moment treatment options remain limited. Having an effective oral therapy will have a major impact for people with MS."

"Our study shows that cladribine tablets prevent relapses and slow down the progression of the disease making patients feel better. Importantly, it does so without the need for constant injections that are associated with unpleasant side effects"

"We will continue to follow the in the trial to see how they fare in the long-term."

Cladribine tablets work by suppressing the immune system, reducing the risk of further damage to a patient's nervous system.

Source: Queen Mary, University of London (news : web)

Explore further: Police seize millions in huge fake Viagra swoop

add to favorites email to friend print save as pdf

Related Stories

Study of bone marrow stem cells in multiple sclerosis

Sep 26, 2007

A new pilot clinical trial to test bone marrow stem cell therapy with a small group of patients with multiple sclerosis has started at Frenchay Hospital. The aim of the trial, conducted by the University of Bristol and North ...

Could estriol be the elixir for MS?

Mar 23, 2007

It has long been common knowledge that pregnant women with multiple sclerosis (MS) experience a sharp drop in the disease's symptoms during the course of their pregnancy.

Milestone for cannabinoid MS study

Jul 21, 2008

The CUPID (Cannabinoid Use in Progressive Inflammatory brain Disease) study at the Peninsula Medical School in Plymouth has reached an important milestone with the news that the full cohort of 493 people with multiple sclerosis ...

Hookworms in MS trial

Mar 03, 2009

Scientists from The University of Nottingham will study the potential health benefits of parasitic worms as part of a study investigating treatments for people with the autoimmune condition multiple sclerosis (MS).

Stem cell transplant reverses early-stage multiple sclerosis

Jan 30, 2009

Researchers from Northwestern University's Feinberg School of Medicine appear to have reversed the neurological dysfunction of early-stage multiple sclerosis patients by transplanting their own immune stem cells into their ...

Drug improves mobility for some MS patients

Feb 27, 2009

The experimental drug fampridine (4-aminopyridine) improves walking ability in some individuals with multiple sclerosis (MS). That is the conclusion of a multi-center Phase 3 clinical trial, the results of which were published ...

Recommended for you

Novartis Japan admits concealing drug side effects

19 hours ago

The Japanese unit of Swiss pharma giant Novartis has admitted it did not report more than 2,500 cases of serious side effects in patients using its leukaemia and other cancer drugs, reportedly including some fatalities.

Most US babies get their vaccines, CDC says

Aug 28, 2014

(HealthDay)—The vast majority of American babies are getting the vaccines they need to protect them from serious illnesses, federal health officials said Thursday.

Expression of privilege in vaccine refusal

Aug 27, 2014

Not all students returning to school this month will be up to date on their vaccinations. A new study conducted by Jennifer Reich, a researcher at the University of Colorado Denver, shows that the reasons why children may ...

User comments : 0